Access Keys:
Skip to content (Access Key - 0)

Center For Cancer Research National Cancer Institute
Clinical Research Operations

Protocol Templates and Forms

1) Protocol Submission and Review

Major changes have occurred in the following 3 sections:

  1. Section 5, biospecimens collection: This raises many questions that should be addressed if the protocol involves genetic/genomic analysis. If these issues are addressed upfront, this can reduce stipulations at the time of IRB review.
  2. Section 7: Has updated language for safety reporting that is required by OHRP, FDA, OBA and IBC, in addition to current language regarding safety monitoring plans.
  3. Section 9, collaborative agreements: This is a new section which has been added so that all collaborations with outside investigators can be clearly identified in one section of the protocol.
Precis:
2) Protocol Deviation and Violations

 Definitions:

Protocol Deviation:  Any change, divergence, or departure from the IRB approved study procedures in a research protocol that does not have a major impact on the subject's rights, safety or well-being, or the completeness, accuracy and reliability of the study data.

Protocol Violation:  Any change, divergence, or departure from the IRB approved study procedures in a research protocol that does have a major impact on the subject's rights, safety or well-being, or the completeness, accuracy and reliability of the study data.

Deviations and Violations are reported to the NCI IRB via iRIS.

3) Informed Consent/Assent
Non-English Speaking Research Subjects:
  • NCI Short Form Addendums version 1 - using optional studies language that was approved prior to April 2012.  Please be sure that the Addendum that you select matches your protocol. 
  • NCI Short Form Addendums version 2 - using optional studies language that was approved after to April 2012.  Please be sure that the Addendum that you select matches your protocol. 
4)  Exemption from IRB Review
Human Biospecimens: